Pharmaceutical company Mylan NV (NASDAQ:MYL) reported on Monday the availability of Mesalamine Delayed-Release Tablets USP in 1.2 g in the US gastroenterology market.
The company added that the Mesalamine Delayed-Release Tablets USP in 1.2 g is the generic version of Shire's Lialda Delayed-Release Tablets.
According to the company, the US Food and Drug Administration (FDA) has approved its Abbreviated New Drug Application (ANDA) for Mesalamine Delayed-Release Tablets USP in 1.2 g for the induction of remission in patients with active, mild to moderate ulcerative colitis (UC) and for the maintenance of remission of UC.
For the 12 months ending 31 October 2018, the US sales for Mesalamine Delayed-Release Tablets USP in 1.2 g were approximately USD842m, according to IQVIA.
Par Pharmaceutical starts shipping colchicine 0.6mg capsules
Padagis launces Brinzolamide Ophthalmic Suspension with CGT exclusivity
Novartis completes Sandoz Spin-off
Novartis completes Sandoz spin-off, focusing on innovative medicines
Hikma marks KLOXXADO two-year anniversary by surpassing 375,000 doses donated in the US
STADA seeks full approval for Kinpeygo in IgA nephropathy from UK MHRA
Azurity Pharmaceuticals completes Slayback Pharma acquisition
Sandoz secures European approval for Tyruko biosimilar in MS treatment
Senores Pharmaceuticals introduces Nicardipine Hydrochloride Capsules USP, 20mg and 30mg in US
Lupin collaborates with Mark Cuban Cost Plus Drug Company and COPD foundation
Certara Simcyp receives FDA grants for advanced pharmacokinetic modelling
Sandoz's Tyruko (natalizumab-sztn) gains FDA approval as first biosimilar for relapsing MS
Nephron Pharmaceutical names new chief procurement officer
Lupin Pharmaceuticals launches Tiotropium Bromide Inhalation Powder, 18mcg/capsule in US